<?xml version="1.0" encoding="UTF-8"?>
<p>It is unclear if ART offers any protection from COVID-19 in HIV patients. However, there have been reports that patients living with HIV and COVID-19 pneumonia receiving ART may have moderate symptoms and faster improvement than the general population and atypical CT imaging features from the conventional population. The preliminary clinical trials showed no clinical benefit of lopinavir/ritonavir for COVID-19 [
 <xref rid="R33" ref-type="bibr">33</xref>]. In a recent clinical case series by Blanco et al, five patients with COVID-19 and HIV who were treated with protease inhibitors regimen recovered well with no deaths reported [
 <xref rid="R67" ref-type="bibr">67</xref>]. The efficacy of ART medications on COVID-19 needs to be further confirmed in future studies so that the management and prognosis of patients co-infected with HIV and COVID-19 might be improved [
 <xref rid="R68" ref-type="bibr">68</xref>].
</p>
